{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2018"],"data_sharing_plan":["IPD Sharing (as of August 2023): Undecided"],"condition":["Adenocarcinoma","Metastatic Colorectal Cancer"],"disease":["Adenocarcinoma","Metastatic Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2277501"],"location":["Martinique","France"],"study_start_month":["4"],"keyword":["Stop and Go strategy","Panitumumab","RAS Wild-type"],"repository":["ECRIN MDR"],"study_status":["Active, not recruiting"],"additional_accession":[]},"is_claimable":false,"name":"FOLFOX + Panitumumab According to a \"Stop and go\" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation","description":"Single-arm, multi-centre phase II study The primary objective is to evaluate the time to failure of the strategy.","dates":{"creation":"2018-04-15"},"accession":"2277501","cross_references":{"ClinicalTrials___gov":["NCT03584711"]}}